Who
Jennifer Lynn Minai-Azary
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Context Therapeutics; Chief Financial Officer, Tempest Therapeutics.
In numbers
- Trades disclosed
- 11
- Buys
- 3
- Sells
- 0
- Bought
- $71K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 26 Feb 2021
- Last trade
- 19 Feb 2026
- Last filed
- 23 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Feb 2026filed 23 Feb 2026 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —275,000 at $0.00 | filing |
| 19 Feb 2026filed 23 Feb 2026 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —275,000 at $0.00 | filing |
| 6 Jun 2025filed 10 Jun 2025 | CNTX Context TherapeuticsBiotechnology | SEC FORM 4 Bought | $26K40,010 at $0.64 | filing |
| 13 Feb 2025filed 14 Feb 2025 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —371,800 at $0.00 | filing |
| 21 Mar 2024filed 22 Mar 2024 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —160,115 at $0.00 | filing |
| 13 Feb 2023filed 14 Feb 2023 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —158,001 at $0.00 | filing |
| 16 Dec 2022filed 19 Dec 2022 | CNTX Context TherapeuticsBiotechnology | SEC FORM 4 Bought | $19K25,000 at $0.74 | filing |
| 17 Aug 2022filed 17 Aug 2022 | CNTX Context TherapeuticsBiotechnology | SEC FORM 4 Bought | $27K15,000 at $1.80 | filing |
| 25 Feb 2022filed 25 Feb 2022 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —112,470 at $0.00 | filing |
| 1 Nov 2021filed 1 Nov 2021 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —52,753 at $0.00 | filing |
| 26 Feb 2021filed 2 Mar 2021 | TPST Tempest Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.